11:34 AM EDT, 10/20/2025 (MT Newswires) -- Immatics ( IMTX ) said Monday that updated data from 16 patients with metastatic uveal melanoma treated with anzu-cel PRAME cell therapy showed continued "strong" anti-tumor activity and durability of response.

The company said data from the ongoing phase 1b trial evaluating anzu-cel show that the confirmed objective response rate was 67%, the disease control rate was 88%, and the median duration of response was 11 months.

Progression-free survival had a median of 8.5 months. At six months, 69% of patients remained progression-free, and at twelve months, the rate was 39%. Median overall survival has not yet been reached, the company said, adding that anti-tumor responses were observed in the liver as well as in other metastatic sites such as the lungs, lymph nodes, and abdominal areas.

The company added that, given the "promising" clinical activity of anzu-cel and high PRAME prevalence in uveal melanoma, a phase 2 cohort has been started in patients with metastatic uveal melanoma.

Shares of Immatics ( IMTX ) rose past 5% in recent trading activity.

Price: 10.41, Change: +0.54, Percent Change: +5.47